Takeda admits running bad ads

Share this article:

Takeda's chief executive admitted that his company used “inappropriate expressions” in promotions of its blood pressure drug Blopress, reports the Wall Street Journal. The Journal notes that the CEO's statement comes after Japan's health ministry said it was going to examine the company's advertisements which used a graph that did not align with clinical trial results that compared Blopress and Pfizer's Norvasc.

The Journal says the company also “admitted using expressions in its ads that could potentially lead to misunderstanding that Takeda's drug was more effective than the rival product.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.